PTGX
Price
$41.41
Change
+$1.86 (+4.70%)
Updated
Dec 20, 04:59 PM (EDT)
85 days until earnings call
VRDN
Price
$19.04
Change
+$0.31 (+1.66%)
Updated
Dec 20, 04:59 PM (EDT)
65 days until earnings call
Ad is loading...

PTGX vs VRDN

Header iconPTGX vs VRDN Comparison
Open Charts PTGX vs VRDNBanner chart's image
Protagonist Therapeutics
Price$41.41
Change+$1.86 (+4.70%)
Volume$62.22K
CapitalizationN/A
Viridian Therapeutics
Price$19.04
Change+$0.31 (+1.66%)
Volume$44.99K
CapitalizationN/A
PTGX vs VRDN Comparison Chart
Loading...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PTGX vs. VRDN commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTGX is a Hold and VRDN is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (PTGX: $41.49 vs. VRDN: $19.03)
Brand notoriety: PTGX and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PTGX: 335% vs. VRDN: 365%
Market capitalization -- PTGX: $2.47B vs. VRDN: $1.51B
PTGX [@Biotechnology] is valued at $2.47B. VRDN’s [@Biotechnology] market capitalization is $1.51B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PTGX’s FA Score shows that 2 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • PTGX’s FA Score: 2 green, 3 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, PTGX is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PTGX’s TA Score shows that 3 TA indicator(s) are bullish while VRDN’s TA Score has 5 bullish TA indicator(s).

  • PTGX’s TA Score: 3 bullish, 6 bearish.
  • VRDN’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, VRDN is a better buy in the short-term than PTGX.

Price Growth

PTGX (@Biotechnology) experienced а +1.00% price change this week, while VRDN (@Biotechnology) price change was +6.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

PTGX is expected to report earnings on Mar 18, 2025.

VRDN is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTGX($2.47B) has a higher market cap than VRDN($1.51B). PTGX YTD gains are higher at: 80.942 vs. VRDN (-12.626). PTGX has higher annual earnings (EBITDA): 152M vs. VRDN (-253.41M). VRDN has more cash in the bank: 753M vs. PTGX (469M). PTGX has less debt than VRDN: PTGX (10.9M) vs VRDN (21.1M). PTGX has higher revenues than VRDN: PTGX (324M) vs VRDN (302K).
PTGXVRDNPTGX / VRDN
Capitalization2.47B1.51B164%
EBITDA152M-253.41M-60%
Gain YTD80.942-12.626-641%
P/E Ratio15.14N/A-
Revenue324M302K107,285%
Total Cash469M753M62%
Total Debt10.9M21.1M52%
FUNDAMENTALS RATINGS
PTGX vs VRDN: Fundamental Ratings
PTGX
VRDN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
4166
SMR RATING
1..100
2298
PRICE GROWTH RATING
1..100
4251
P/E GROWTH RATING
1..100
21100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PTGX's Valuation (65) in the Biotechnology industry is in the same range as VRDN (92). This means that PTGX’s stock grew similarly to VRDN’s over the last 12 months.

PTGX's Profit vs Risk Rating (41) in the Biotechnology industry is in the same range as VRDN (66). This means that PTGX’s stock grew similarly to VRDN’s over the last 12 months.

PTGX's SMR Rating (22) in the Biotechnology industry is significantly better than the same rating for VRDN (98). This means that PTGX’s stock grew significantly faster than VRDN’s over the last 12 months.

PTGX's Price Growth Rating (42) in the Biotechnology industry is in the same range as VRDN (51). This means that PTGX’s stock grew similarly to VRDN’s over the last 12 months.

PTGX's P/E Growth Rating (21) in the Biotechnology industry is significantly better than the same rating for VRDN (100). This means that PTGX’s stock grew significantly faster than VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PTGXVRDN
RSI
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
82%
Momentum
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
86%
MACD
ODDS (%)
Bearish Trend 4 days ago
74%
Bullish Trend 4 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 28 days ago
81%
Declines
ODDS (%)
Bearish Trend 6 days ago
75%
Bearish Trend 5 days ago
85%
BollingerBands
ODDS (%)
N/A
Bullish Trend 4 days ago
82%
Aroon
ODDS (%)
Bearish Trend 4 days ago
72%
Bearish Trend 4 days ago
87%
View a ticker or compare two or three
Ad is loading...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GRESX11.360.19
+1.70%
Goldman Sachs Real Estate Securities Svc
APDLX14.260.14
+0.99%
Artisan Value Advisor
JUSSX18.070.17
+0.95%
JPMorgan US Small Company L
FWWFX35.150.28
+0.80%
Fidelity Worldwide
RNWAX74.090.11
+0.15%
American Funds New World R1

PTGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been loosely correlated with ACLX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if PTGX jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
+4.93%
ACLX - PTGX
41%
Loosely correlated
+0.44%
ARDX - PTGX
41%
Loosely correlated
+2.77%
BEAM - PTGX
40%
Loosely correlated
+8.04%
VRDN - PTGX
40%
Loosely correlated
+1.60%
REPL - PTGX
40%
Loosely correlated
+4.00%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with ALLO. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+1.60%
ALLO - VRDN
52%
Loosely correlated
+1.63%
FATE - VRDN
50%
Loosely correlated
+1.20%
AURA - VRDN
46%
Loosely correlated
+1.11%
CRBU - VRDN
46%
Loosely correlated
-0.55%
ABCL - VRDN
45%
Loosely correlated
+5.17%
More